Metagenomi Therapeutics, Inc. Insider Trading Activity

Metagenomi Therapeutics Chief Financial Officer Pamela Wapnick reported new equity awards.

Accepted by SEC EDGAR 04/03/2026 - 01:40 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Metagenomi Therapeutics Chief Financial Officer Pamela Wapnick reported new equity awards. She received a grant of 144,000 stock options with an exercise price of $1.34 per share, expiring on March 31, 2036. These options relate to 144,000 shares of common stock.

She was also granted 24,000 shares of common stock in the form of restricted stock units. Twenty-five percent of the RSUs vest on June 5, 2027, with the rest vesting in 12 equal quarterly installments. Her directly owned common stock holdings total 211,375 shares after these grants. The option award vests 25% on April 1, 2027, with the remainder vesting in 36 equal monthly installments.

Insider Trade Summary

Grant/Award: 168,000 shares

Grant/Award 2 txns

Insider Wapnick Pamela

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	144,000	$0.00	$0.00
Grant/Award	Common Stock	24,000	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 144,000 contracts (Direct); Common Stock — 211,375 shares (Direct)

Footnotes (2)

1. F1. These shares represent restricted stock units ("RSUs"). 25% of the RSUs shall vest on June 5, 2027, with the remainder vesting in 12 equal quarterly installments thereafter, subject to the Reporting Person's continued service with the Issuer on each such vesting date.
2. F2. 25% of the shares subject to this option shall vest and become exercisable on April 1, 2027, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service with the Issuer on each such vesting date.

Key Figures

Stock options granted: 144,000 options Option exercise price: $1.34 per share Option expiration: March 31, 2036 +4 more

7 metrics

Stock options granted 144,000 options Grant to CFO on April 1, 2026

Option exercise price $1.34 per share Exercise price for 144,000 options

Option expiration March 31, 2036 Expiry of newly granted options

RSUs granted 24,000 RSUs Restricted stock units granted to CFO

RSU initial vesting date June 5, 2027 25% of RSUs vest on this date

Shares held after grant 211,375 shares Direct common stock holdings after RSU grant

Option vesting start April 1, 2027 25% of options vest and become exercisable

Key Terms

restricted stock units ("RSUs"), Stock Option (Right to Buy), exercise price, vest, +1 more

5 terms

restricted stock units ("RSUs") financial

"These shares represent restricted stock units ("RSUs"). 25% of the RSUs shall vest on June 5, 2027..."

Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.

Stock Option (Right to Buy) financial

"security_title: "Stock Option (Right to Buy)" for 144000.0000 shares..."

exercise price financial

"conversion_or_exercise_price: "1.3400" per share for the stock option grant..."

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vest financial

"25% of the shares subject to this option shall vest and become exercisable on April 1, 2027..."

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

expiration date financial

"expiration_date: "2036-03-31T00:00:00.000Z" for the stock option grant..."

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Wapnick Pamela

(Last) (First) (Middle)

C/O METAGENOMI THERAPEUTICS, INC.

5959 HORTON STREET, 7TH FLOOR

(Street)

EMERYVILLE CALIFORNIA 94608

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Metagenomi Therapeutics, Inc. [ MGX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	04/01/2026		A		24,000(1)	A	$0	211,375	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$1.34	04/01/2026		A		144,000		(2)	03/31/2036	Common Stock	144,000	$0	144,000	D

Explanation of Responses:

1. These shares represent restricted stock units ("RSUs"). 25% of the RSUs shall vest on June 5, 2027, with the remainder vesting in 12 equal quarterly installments thereafter, subject to the Reporting Person's continued service with the Issuer on each such vesting date.

2. 25% of the shares subject to this option shall vest and become exercisable on April 1, 2027, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service with the Issuer on each such vesting date.

	/s/ Matthew L. Wein, attorney-in-fact	04/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)